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Abstract
Drug combinations are highly efficient in systemic treatment of complex multigene diseases
such as cancer, diabetes, arthritis and hypertension. Most currently used combinations
were found in empirical ways, which limits the speed of discovery for new and more effective
combinations. Therefore, there is a substantial need for efficient and fast computational
methods. Here, we present a principle that is based on the assumption that perturbations
generated by multiple pharmaceutical agents propagate through an interaction network and
can cause unexpected amplification at targets not immediately affected by the original
drugs. In order to capture this phenomenon, we introduce a novel Target Overlap Score
(TOS) that is defined for two pharmaceutical agents as the number of jointly perturbed tar-
gets divided by the number of all targets potentially affected by the two agents. We show
that this measure is correlated with the known effects of beneficial and deleterious drug
combinations taken from the DCDB, TTD and Drugs.com databases. We demonstrate the
utility of TOS by correlating the score to the outcome of recent clinical trials evaluating tras-
tuzumab, an effective anticancer agent utilized in combination with anthracycline- and tax-
ane- based systemic chemotherapy in HER2-receptor (erb-b2 receptor tyrosine kinase 2)
positive breast cancer.
Introduction
In the past few decades the number of novel marketed drugs has fallen much below the expec-
tations despite the growing resources invested in this area [1–3]. Many biological pathways
have rich regulatory loops which can be utilized to compensate various perturbations. In cancer
therapy, drugs acting on the HER2 (erb-b2 receptor tyrosine kinase 2) and EGFR (epidermal
growth factor receptor) pathways have shown this type of drug evasion effects. Multitarget
drugs or drug combinations have been proposed as a general strategy to circumvent this
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phenomenon [4, 5] one of the reasons being that combinations often have less toxicity and
higher therapeutic success [6]. The number of approved drug combinations is on the increase,
even though most of them were established by experience and intuition [7, 8].
About one-fourth of breast cancer patients express HER2 (human epidermal growth factor
receptor-2), a transmembrane receptor tyrosine kinase of the epidermal growth factor receptor
(EGFR) family. In HER2 positive patients, administration of trastuzumab, an anti-HER2 thera-
py improved the progression free survival (PFS) and the overall survival (OS) [9]. It also en-
hanced survival as adjuvant therapy combined with chemotherapy [10] or as monotherapy
after chemotherapy [11]. Since 2006, trastuzumab is also approved for use in adjuvant settings
in HER2 positive early breast cancer. Anti-HER2 therapy is highly successful: although high
HER2 expression was previously associated with worse survival, today HER2 positive patients
have better prognosis as compared to women with HER2 negative disease [12].
According to current NCCN guidelines (www.nccn.org), trastuzumab is given in combina-
tion with adjuvant chemotherapy only. Preferred regimes for chemotherapy with trastuzumab
include Adriamycin, Cyclophosphamide, Paclitaxel, Docetaxel and Carboplatin. Numerous
other agents are also included in protocols used for breast cancer patients including Metho-
threxate, Epirubicine, Fluorouracil and protocols containing combinations of these (FAC,
CAF, CMF, EC, FEC, TAC, etc.). Thus, the combination of various agents into multi-agent
protocols represents the backbone of the state of the art in systemic treatment for HER2 posi-
tive breast cancer. However, finding the most efficient combinations of these is not an easy task
given the complexity of the underlying biological system.
Several experimental methods, even high throughput methods [13], have been developed
for measuring efficiency of drug combinations, such as Bliss independence or Loewe additivity
[14–16]. Wong et al. used a stochastic search algorithm [17] while Calzoari and associates em-
ployed sequential decoding algorithms for finding the best combinations [18]. Yang et al. used
differential equations to find a perturbation pattern that can revert the system from disease
state to a normal state [19]. Jin and associates employed a Petri net based model to microarray
data in order to predict synergism of drug pairs [20]. A common feature of these computation-
al methods is that they require a large number of experiments or deep knowledge of the kinetic
parameters of the pathways even if the search space is small.
Other studies used various combinations of data mining methods to integrate pharmacolog-
ical and network data [21, 22]. Li and coworkers used the concept of network centrality and
disease similarity to prioritize drug combinations [23]. Wu and associates used the microarray
profile of the individual drugs for the predictions [21], and others used the concept of synthetic
lethality and the available gene interaction data [24, 25]. Despite the countless attempts, there
are still many challenges and open practical questions. In particular, finding suitable data rep-
resentations and similarity measures is not a trivial problem because of the heterogeneity of in-
formation sources. Currently there are published data on a large number of drug combinations
(six hundred in the DCDB and TTD databases as of March 2013), that refer to a variety of dis-
eases and therapeutic targets. It is an open question whether or not the correlations and ten-
dencies extracted from such heterogeneous datasets can be successfully applied to a specific
problem, such as that of trastuzumab.
Here we present a novel principle that is based on the assumption that perturbations gener-
ated by the pharmacological agents propagate through an interaction network to other targets
that constitute what we call a propagation neighborhood. Overlaps of multiple propagation
neighborhoods can then cause unexpected synergies at target genes that are not in the immedi-
ate vicinity of the original targets of the individual agents. We introduce a novel Target Overlap
Score (TOS) that is based on the overlap of the propagation neighborhoods of the target pro-
teins. We show that TOS is correlated with the known efficiency of beneficial and deleterious
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effects of drug combinations reported in the DCDB, TTD and Drugs.com databases. We also
show that there is a correlation between TOS and the outcome of recent clinical trials where
trastuzumab was used in combination with anthracycline- and taxane- based systemic chemo-
therapy in HER2-receptor positive breast cancer.
Results
2.1. TOS: A network-based Target Overlap Score for drug combinations
Drug molecules reach their therapeutic effects by acting on specific targets in the organism and
activating or inhibiting the functions of their targets. Drug effects naturally do not end here,
since drug targets are members of large interaction networks through which the perturbation
can propagate. For instance, by inhibiting the action of a single molecule such as BRAF (B-Raf
proto-oncogene, serine/threonine kinase), the entire RAF/MEK/ERK (Raf-1 proto-oncogene,
serine/threonine kinase, mitogen-activated protein kinase kinase 1, mitogen-activated protein
kinase 1) pathway will be tuned down, and as a consequence, collateral pathways including
PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) and RALA (v-ral simian leukemia viral
oncogene homolog A (ras related)) will also be affected. In other words, a drug acting on a sin-
gle target will concomitantly perturb a group of linked targets that we term here as network
neighborhood (Fig 1). We hypothesize that two (or more) drugs can have an unexpected com-
bined effect if their perturbation neighborhoods overlap. In order to capture this property, we
define a Target Overlap Score (TOS) for two drugs as the number of jointly affected targets di-
vided by the number of all affected targets. This simple definition has a few plausible conse-
quences: i) TOS has a value between zero and 1.0, higher values indicating stronger joint
effects. ii) As a mathematical consequence, a drug will give TOS = 1.0 with itself. We note that
even though a combination of two identical drugs does not occur in the clinical practice it can
cause a statistical bias in the comparisons so they have to be removed from the datasets used in
the statistical comparison (see Methods for details). iii) The concept of TOS can be generalized
to more than two interacting drugs. Naturally, we have to decide in advance if, at one extreme,
we want to consider genes perturbed by more than one agent in a drug combination only, or, at
Fig 1. The network-interaction hypothesis. The effects of two drugs (Drug1, Drug2) reach their imminent
targets first (arrows) and the effects will then propagate to their network neighborhoods (subnetworks)
indicated in red and green, respectively. Targets in the overlap are affected by both drugs, and we suppose
that drugs affecting a number of common targets will influence the effects of each other. The overlap is
quantified as the proportion of jointly affected targets within all affected targets (in set theory terms: intercept
divided by union).
doi:10.1371/journal.pone.0129267.g001
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the other extreme, we consider just those genes that are perturbed by all of them. Here we used
the former definition (for a detailed description see Data and Methods). iv) The concept of
TOS does not include any supposition about the beneficial or detrimental nature of combined
drug effect. This is an important point since “drug interaction” in pharmacology denote nega-
tive, detrimental effect while the term “drug combinations” usually refer to beneficial, i.e. thera-
peutically useful combined effects. In principle TOS can be correlated with both as we in fact
show in the next chapter. v) Finally, the definition of TOS is different from several other con-
cepts related to traditional measures of drug interactions (antagonism, agonism etc) that most-
ly refer to effects of drugs on the activity of one target such as a receptor. In contrast, TOS
depends on the number of targets, and does not at present consider the magnitude (nor the
positive or negative nature) of the effect.
2.2. TOS is correlated with the strength of both beneficial and
deleterious drug combinations
For the evaluation we chose a simple ranking test, i.e. we compared the TOS value calculated
for known drug pairs with the TOS or randomly chosen drug pairs and calculated an AUC
value for the ranking using ROC analysis [26] as described in methods (section 4.5). It is noted
that strong interactions are expected to give AUC values close to 1.0 while AUC values for ran-
domly selected pairs are expected to be around AUC ~ 0.5. In the present study we used the
STRING/STITCH interaction network and the first question we asked was whether or not the
evaluation system fulfils these fundamental criteria, For this purpose we used the database of
FDA-approved drugs [27] and generated all possible binary combinations. Trivial interactions
(drugs acting on the same target and drug pairs with identical or nearly identical chemical
structures) as well as drug pairs known to have positive or negative effects were omitted from
the analysis which left 733542 pairs. This set was evaluated as described in methods (Section
4.5). This evaluation gave an AUC value of 0.48 (Fig 2, left) which is very close to the random
value of 0.5 This finding thus shows that, given the TOS algorithm applied to the STRING/
STICTH network, the randomly chosen FDA-approved drug pairs indeed behave as random.
We have to mention that the randomly selected drug pairs may have contained cases in which
the interaction has not been discovered yet. A related question is that of drugs having identical
targets. These should by definition give a TOS value of 1.00, and we found 271 such drug pairs.
Also, drugs having close to identical chemical structures are likely to affect similar targets. We
found 179 such drug pairs but only 8 of these were common with the previous subset. The
comparison shows that both subsets give high TOS values which will statistically bias the com-
parison if included either in the positive or in the negative dataset of non-interacting drugs. So,
for the statistical evaluation described below we left out these drug pairs from both datasets.
Next, we wanted to test whether or not TOS can help to identify the drug pairs that are em-
pirically known to have a beneficial or detrimental effect. In pharmacology, two drugs are
called "interacting" if their joint administration has a detrimental effect [28]. Drug pairs listed
at http://drugs.com are classified into three groups according to the severity of the negative ef-
fects, such as major, moderate and minor. In the selection we considered only cancer related
drug pairs i.e. those in which one of the agents was or was proposed to be used in treating can-
cer which resulted in 10323 strongly, 92958 moderately and 17193 weakly interacting drugs
from the database, denoted as sets A, B and C, respectively (Table 1). The results show that the
interacting drug pairs show remarkably higher AUC values than the randomly selected drug
pairs, moreover these values qualitatively follow the strength of the interaction (Fig 2). Namely,
strongly interacting drug pairs show substantially higher AUC values than the moderately in-
teracting ones etc.
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We also tested drug pairs that are known to have a beneficial effect when administered to-
gether. In pharmacology, the term “drug combinations” refers to drugs that are administered
together because they have an empirically known beneficial therapeutic effect. Such therapeuti-
cally useful drug combinations are included in the Drug Combination Database (DCDB) [29]
as well as in the Therapeutic Target Database TTD [30], along with the specific mechanism of
their interaction. Using the same selection criteria we 293 combinations (dataset D, Table 1).
The results in Fig 2, right show that therapeutic drug combinations yield AUC values substan-
tially different from the random combinations.
Next we carried out the same comparisons for cancer related drugs. In this case the datasets
were naturally smaller, we found 817 strongly, 5700 moderately and 241 weakly interacting
drugs from the database, and denoted as sets E, F and G, respectively (Table 1). The set of bene-
ficial combinations included 33 combinations specifically suggested for cancer (dataset H,
Table 1). The results presented in Fig 2B show the same general tendencies as seen in the case
of all drug combinations (Fig 2A). Namely, i) the known interactions are substantially different
from the combinations of non-interacting drugs; ii) the AUC values of minor, moderate and
strong, detrimental interactions follow the correct order i.e. the stronger the interactions the
higher the AUC values; and iii) the values of beneficial, therapeutic combinations is also sub-
stantially different from the average and the AUC value of 0.91 in cancer related combinations
Fig 2. Ranking performance of the TOS score on known drug interactions and therapeutic combinations. The ranking performance was measured via
ROC analysis as described in Data and Methods. The standard deviation of AUC values (not shown) are between 0.0001 and 0.006 for the different
datasets. Note that the tendencies of drug combination groups are the same between cancer-related and not cancer-related drugs. Also, combinations of
drugs with identical targets or with similar chemical structures give high TOS scores. These combinations were left out from the statistics of the other groups
so they do not influence the AUC values of the other groups.
doi:10.1371/journal.pone.0129267.g002
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can be considered especially convincing. iv) In both panels of Fig 2, the beneficial interactions
show higher AUC values. We have no ready explanation for this phenomenon, however we
speculate that one of the reason could be that therapeutic combinations are usually optimized
via careful clinical studies.
2.3. TOS vs. GO and ATC codes
Since TOS is conceptually different from other measures used to characterize drug interactions,
one might expect that additional parameters successfully used in other studies can increase its
ranking power. The most obvious way of boosting the performance of a classifier is to include
more and more relevant knowledge on the drugs. Earlier studies suggest that the integration of
disease similarity [23] or therapeutic information such as ATC code based similarity [22, 31, 32]
as well as target similarity, such as GO annotations could be useful as well [22, 25]. In order to
test these possibilities, we combined TOS with GO or ATC based similarity metrics using logistic
regression [33], a standard method in machine learning studies, as described in methods. The re-
sults in Fig 3 show that inclusion of new parameters did not substantially change the picture.
The fact that the ranking power of TOS was not substantially improved when other parame-
ters were added shows that TOS in itself captures a property that is well correlated with the em-
pirically known interaction strength of various drug combinations.
Table 1. Datasets.
Dataset Original size Size after ﬁltering1 Data source
I. Datasets of all drugs
Detrimental drug interactions2
Severe A 21831 10323 Drugs.com
Moderate B 112976 92958 Drugs.com
Minor C 13143 17973 Drugs.com
Beneﬁcial drug interactions3, 4 D 429 293 DCDB, TTD
II. Cancer-related datasets
Detrimental drug interactions2
Severe E 1053 817 Drugs.com
Moderate F 6857 5700 Drugs.com
Minor G 273 241 Drugs.com
Beneﬁcial drug interactions3, 5 H 55 33 DCDB, TTD
III. Negative datasets used in ROC analysis
All FDA-approved drugs6 I 848253 733542 Drugbank
Random drugs7 J 427350 426425 -
1We ﬁltered the available drug pairs by leaving out the drug combinations where the components have exactly the same targets, or the components were
structurally similar, as described in Methods. The drugs with no available targets were also discarded
2Taken from Drugs.com (November 11, 2013) as described in the methods
3Taken from the Drug Combination Database (March 8, 2012) and the Therapeutic Target Database (July 23, 2012) as described in the methods
4All approved drug combinations were included
5All approved drug combinations that are used in cancer treatment.
6We made all possible binary combinations of FDA-approved drugs (taken from DrugBank, 12th September of 2012), and then leaved out all pairs that
were listed as beneﬁcial or detrimental combinations.
7We constructed random drugs corresponding to the number of targets of all individual drugs. We generated 25 random drugs for each target count (37).
From this pool we made the all possible binary combinations. In each case, we randomly selected a negative set of the size which was 5 times greater
than the positive dataset [51].
doi:10.1371/journal.pone.0129267.t001
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2.4. TOS shows correlation with the outcome of clinical trials
In a clinical trial (also called „interventional study”), patients receive specific interventions ac-
cording to a well-defined protocol [34]. In our case, trial data were collected from http://
clinicaltrials.gov and consisted of studies in which combinations included trastuzumab either
as an interaction partner or as a basis for comparison and only those clinical scores were used
that were collected according to RECIST [35]. The list of drugs tested in clinical trials included
bevacizumab, capecitabine, carboplatin, cyclophosphamide, docetaxel, doxorubicin, epirubicin,
fluorouracil, gemcitabine, ixabepilone, lapatinib, oxaliplatin, paclitaxel, pertuzumab, sunitinib.
All the clinical response data are listed in S1 Table.
First we analyze the statistical dependence between the clinical outcomes and the TOS val-
ues calculated for the drug regimens used for the treatment. Several regimens included more
than two agents, such as trastuzumab and three additional drugs, A, B and C. Spearman's rank
correlation coefficient was used for quantifying the statistical dependence between the TOS
score and the clinical outcome measures. Table 2 shows that the TOS score shows substantial
correlation with the overall response (OR) (r = 0.64; p = 0.0028)–Fig 4. Furthermore, the over-
all survival rate (OSR) and Confirmed Clinical Benefit (CCB) correlate well with TOS r = 0.87;
p = 0.017 and r = 0.84; p = 0.0021).
In conclusion, the data suggest that there is a significant correlation between the TOS scores
and the outcome of clinical trials.
Fig 3. Performance of combined predictors on different training sets. The short titles TOS, TOS+ATC, TOS+GO or TOS+GO+ATC refer to the
combination used. The curves represent the AUC value distribution (as a probability density function) obtained via a kernel density estimation (KDE)
approach. The data were obtained by a 5 fold cross-validation procedure described in Methods (section 4.5). Note that the distributions are quite similar to the
TOS values (top left) which indicates that TOS effectively captures the drug combination phenomenon.
doi:10.1371/journal.pone.0129267.g003
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Discussion
The TOS score is based on the intuitive expectation that drugs perturbing overlapping neigh-
borhoods within a gene network will combine their effects either in the positive or in the nega-
tive sense, and that the strength of the combined effect is proportional to the ratio of jointly
affected targets within all affected targets. The TOS measure will detect the overlap, but a high
TOS will not tell if the variations are caused by positive or by negative synergies. Our tests
showed that TOS is in a consistently good correlation with both, and that this correlation could
not be substantially strengthened by including GO and ATC terms.
A special advantage of TOS is the ability to rank potential drug combinations, so in addition
to the best combination it can also show how the other potential combinations perform in a
relative comparison. The examples in Table 3 list cases where trastuzumab was combined with
a cytotoxic drug (binary combination), or was part of a larger regimen consisting of more
drugs which were studied in clinical trials. The results illustrate our message for trastuzumab:
Table 2. Spearman correlation between the clinical outcomemeasures and the generalized TOS
scores of multicomponent combinations.
Clinical outcome1 r2 p-val.3
OR4 0.6453 0.0028
OSR5 0.8729 0.0175
CCB6 0.8440 0.0021
median PFS7 0.3784 0.4008
1All the clinical outcome measures were recorded based on the Response Evaluation Criteria in Solid
Tumors (RECIST)[35]
2Spearman's rank correlation coefﬁcient
3p-values for Spearman's rank correlation coefﬁcient
4Overall Response
5Overall Survival Rate
6Conﬁrmed Clinical Beneﬁt
7Median Progression Free Survival
doi:10.1371/journal.pone.0129267.t002
Fig 4. Scatter plot of TOS scores and Overall Response. The predicted scores are on the x axes, the clinical outcome, Overall Response (for the definition
of outcomemeasures see the RECIST [35]) are on the y axes. Each data point corresponds to a multicomponent combination. The generalized TOS score of
multicomponent combinations was calculated as described in Data and Methods.
doi:10.1371/journal.pone.0129267.g004
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highest ranking scores were achieved by combinations containing docetaxel. In addition, the
most potent single agent to be administered with trastuzumab was also docetaxel. A few agents
reached low scores (cyclophosphamide, oxaliplatin, carboplatin, ixabepilone) when applied to-
gether with trastuzumab. But interestingly, some of these like cyclophosphamid and epirubicin
have achieved much higher scores when applied in complex regimens which underlies the
complex nature of the therapeutic response. In this context it is worth to note that we apparent-
ly cannot yet estimate whether TOS can help to predict progression free survival which is one
the most important measure of clinical outcomes.
The larger the score the stronger the interaction.
Even though the correlation of TOS with drug combination data is promising, its eventual
use in predictive settings has important limitations. First, TOS relies on the protein-protein (or
gene-gene) interaction data available in the databases. Though such data are accumulating at a
growing pace, interactions missing from the current datasets may lead to erroneous predictions.
An important property of the TOS score is that it can not by itself differentiate between positive
and negative effects. So a high TOS value can mean either a positive, synergistic effect or a nega-
tive, deleterious drug interaction effect. As more information becomes available on the direction,
strength and type (such as inhibiton, activiation, binding, etc.) of the interactions between the
drug targets, some of the above limitations will be gradually eliminated. We also mention that
completely or partly identical targets will by definition lead to high TOS values. While the for-
mer are trivial, the second may be worth while to evaluate. The distinction is not built into the
TOS score itself, but these cases can be identified by straightforward computations.
In addition, there is a conceptual difference between TOS and many of the other concepts of
drug interactions. Namely, TOS does not limit drug-drug interactions or perturbations to iden-
tical drug targets or affected pathways. Instead, TOS captures a multitarget effect, and we think
this is why the direction of the combined effect (i.e. beneficial vs. deleterious). can not be easily
captured by the measure. Here a note on “beneficial” vs. “detrimental” effects is perhaps in
place. Namely, many of the current, therapeutically useful drugs, including immunosuppres-
sants or anti-cancer drugs are effective because they are toxic to a restricted population of cells.
In the context of a single biochemical network, such effects would be considered as deleterious,
Table 3. TOS scores of binary andmulticomponent combinations.
Trastuzumab in binary combinations1 TOS score2 Trastuzumab in multiple combinations1 TOS score2
tra+doc 0.4138 tra+lap+5fu+cyc+epi+pac 0.7272
tra+gem 0.4067 tra+5fu+cyc+epi+pac 0.6629
tra+ﬂu 0.3888 tra+doc+sun 0.6548
tra+pac 0.3732 tra+per+doc 0.6133
tra+dox 0.2509 tra+dox+doc 0.6058
tra+epi 0.1105 tra+cap+doc 0.5108
tra+cap 0.0845 tra+bev+doc 0.4707
tra+cyc 0.0806 tra+gem+car 0.4170
tra+ixa 0.0441 tra+ixa+car 0.0544
tra+oxa 0.0155
tra+car 0.0110
1All combinations presented here were under clinical investigation as of 1st of January 2013. Components in the combinations were lapatinib (lap),
ﬂuorouracil (5fu), cyclophosphamid (cyc), epirubicin (epi), paclitaxel (pac), pertuzumab (per), docetaxel (doc), carboplatin (car), doxorubicin (dox),
gemcitabine (gem), carboplatin (car), ixabepilone (ixa), oxaliplatin (oxa)
2The scores were computed using the generalized TOS as described in Data and Methods.
doi:10.1371/journal.pone.0129267.t003
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even though in the therapeutic sense they are beneficial to the entire organism. We think it is
the task of experimental studies to decide whether or not a combination with outstanding TOS
score is therapeutically useful.
Summarizing, in this paper we presented the Target Overlap Score, a novel computational
method for characterizing drug interactions, based on propagation neighborhoods in protein-
protein interacton networks. The score is based on the hypothesis that those drugs that share a
large number of perturbed proteins will have a combined effect that may be worth studying by
experimental method. The ranking of the candidate combinations showed good correlation
with clinical studies, so we hope this approach can contribute in the future to the design of
therapeutically useful drug combinations.
Data and Methods
4.1 Data sets
The protein-protein interaction data were taken from the STRING database [36] (http://string.
embl.de/, retrieved on 28th august of 2012). The drug related data (drug targets, synonyms, ali-
ases, ATC codes) were taken from the Drugbank [27] via the JBioWH [37] (https://code.
google.com/p/jbiowh/, retrieved on 12th September of 2012), STITCH [38] (http://stitch.embl.
de/, retrieved on 4th September of 2012) and TTD [30] (http://bidd.nus.edu.sg/group/TTD/ttd.
asp, retrieved on 23th July of 2012) databases. The drug interaction data were taken from
http://drugs.com/ (retrieved on 11th November of 2013). The drug combination data were
taken from the DCDB [29] (http://www.cls.zju.edu.cn/dcdb/, 4th March of 2012), and TTD
[30] (http://bidd.nus.edu.sg/group/TTD/ttd.asp, retrieved on 23th July of 2012) databases.
From the STRING database the human protein-protein association and their combined
confidence scores were used. From the STITCH database only those drug-protein associations
were considered which had i) experimental evidence or ii) database evidence with at least 0.800
confidence, and the overall confidence was at least 0.900. Molecules such as Na+, Ca2+, ATP,
etc. that had more than 45 targets were exluced from the dataset. All filtering algorithms were
implented in MATLAB R2014a.
Published clinical trial data on trastuzumab were collected from the ClinicalTrials database
(www.clinicaltrials.gov) using the word ‘trastuzumab’ in pairwise combination with all the 43
chemotherapeutic agents approved for breast cancer (amsacrine, azacitidine, bleomycin, caba-
zitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cladribine, cyclophosphamide,
cytarabine, dacarbazine, daunorubicin, daunorubicin (liposomal), docetaxel, doxorubicin, epir-
ubicin, estramustine, etoposide, fludarabine, fluorouracil, gemcitabine. idarubicin, ifosfamid,
irinotecan, ixabepilone, lomustine, mercaptopurine, methotrexate, mitomycin-c, mitoxan-
trone, nelarabine, oxaliplatin, paclitaxel, pemetrexed, pentostatin, temozolomide, teniposide,
thioguanine, topotecan, vinblastine, vincristine, vinorelbine) on the 1st of January 2013. Clini-
calTrials.gov is developed by the U.S National Institute of Health and contains summary infor-
mation about clinical studies conducted all over the world. Only 18 agents were studied in
combination with trastuzumab in 81 trials. The findings were narrowed to trials in which the
effect of the combined therapy was studied (n = 43). For trials in which trastuzumab was stud-
ied in combination with more than one agent, these duplicates were included only once. Only
the data recorderd according to Response Evaluation Criteria In Solid Tumors Criteria
(RECIST) [35] were used. S1 Table contains the trials with clinical data. Overall clinical re-
sponse (rate) (OR) was calculated from percentage of patients with complete response (CR)
and partial response (PR) (OR = CR + PR) [35]. The Confirmed Clinical Benefit (CCB) was
calculated from CR, PR and stable disease (CCB = CR + PR + SD) [35]. Finally the median pro-
gression free survival (PFS) and the median overall survival (OS) data were added in months.
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4.2. The Target Overlap Score
We define a quantitative Target Overlap Score for two drugs as the ratio of jointly affected tar-
gets within all affected targets (Fig 1, above). The underlying model is that drug effects are local
perturbations in a gene/protein interaction network and that perturbation can propagate along
the network [39]. In order to bring this hypothesis into a testable form, we need to choose i) a
method to model the perturbation of genes within a network; ii) a quantitative measure for
characterizing and comparing the overlapping gene neighborhoods; and iii) networks on
which to calculate the perturbations.
i. Perturbations in interaction networks are often described by diffusion models (TOS) that a
perturbation to spread along the edges of a network is similar to physical diffusion [40].
These models were successfully used for an analogous task, the so-called gene prioritization
problem [41–44] (see Methods for details).
ii. We defined network neighborhood as the set of genes that are significantly perturbed by a
drug. This was determined by Monte Carlo simulation, by repeating the diffusion process
10,000 times and determining the nodes (genes) whose activity changed at a chosen level
significance (e.g. p<0.05) (see Methods for details). As a numerical measure for drug-drug
interaction we define the Target Overlap Score (TOS) as the Jaccard coefficient (similarity
measure between sets) calculated between the neighborhoods significantly affected by a pair
of drugs. TOS is 1.00 for a pair of drugs affecting the same targets and 0.00 for agents that
do not significantly affect any target in common. Performance of TOS (or any other combi-
nation measure) can be characterized by ranking their performance which can be deter-
mined by a standard ROC analysis/AUC calculation (see Methods) [26].
iii. For testing the methods we used the STRING, one of the largest available protein interac-
tion databases [45]. The type of interactions are both physical and indirect (i.e. genes are
coexpressed), furthermore the database contains a large number of predicted protein
interactions.
For the actual testing we also took into consideration that additional data such as functional
annotations and therapeutic information may enhance the performance of a predictive index
such as TOS [22, 23, 32]. We thus integrated TOS with two other drug-similarity measures
taken from the literature: a) the similarity of functions between the immediate targets (GO)
[46] and b) the similarity of ATC codes (ATC) [32], respectively. For the integration of the
similarity measures we trained a logistic regression model [33] that automatically weights the
integrated data sources and normalizes the results. Training process needs positive and nega-
tive training sets. Here the positive training samples are known drug combinations or known
drug interactions, taken from databases. However, confirmed “bad combinations” that could
have been used as negative training sample are not available in such a large amount as the posi-
tive ones (only a couple of confirmed negative combinations are available in current databases).
Thus we used random generated drugs as negative samples. Targets of random generated
drugs are also targeted by known drugs. The reason behind this approach is that the druggable
targets may be limited [2].
4.3. Calculation of drug interaction measures
Graph kernels can reveal important feutares of the graph structures such as network neigh-
bourhood. We used the Regularized Laplacian Exponential Diffusion Kernel (Kμ,α) (TOS) [47]
for that purpose. The significance of a node being affected was estimated by Monte-Carlo sim-
ulations [48], and nodes with significance below a threshold value (typically 0.05) were
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considered as part of the drug target’s network neighborhood. More formally, the network is a
graph G(V,E) where V, E are the set of nodes and edges, respectively. In this case the nodes rep-
resent genes or proteins, and the edges are the associations between them. The edges may have
a weight, which can be interpreted as an association strength. Let A be the adjacency matrix of
the graph. The element aij s the weight of the edge between node i and j, if there is no edge then
it is 0.
Where G is a diagonal matrix, where gi ¼
XjVj
j¼1
Aij
For that purpose the Regularized Laplacian Exponential Diffusion Kernel (Kμ,α) (TOS) [47]
were used. The formula of that kernel is:
Km;a ¼
X1
k¼1
ða
k
k!
LmÞk ¼ eaLm ð1Þ
where Lμ is the regularized Laplacian of the graph:
Lm ¼ mG A ð2Þ
The ith drug (Di) perturbation can be expressed with vector:
SDCMðDiÞ ¼ Km;ap0 ð3Þ
where p0
p0 ¼
1; if the protein i is drug target
0; otherwise
 !
ð4Þ
The th element of S(Di) measures the disruption effect of Di on protein j.
We used the parameters μ = 0.1 and α = 0.005 throughout this study.
Then the network neighborhood consists of the signifacntly perturbed network elements:
neighborhooddrug ¼ fvjjvj 2 V ; p valuej < 0:05g; ð5Þ
The drug interaction measure (TOS) was then calculated as the overlap of two neighbor-
hoods. The overlap was described by the Jacquard coefficient of the two affected sets (see
Fig 1), defined as the intercept of two sets divided by the union of the sets.
TOSðdrugi; drugjÞ ¼
jneighborhooddrugi\neighborhooddrugj j
jneighborhooddrugi[neighborhooddrugj j
; ð6Þ
This measure is easily generalized to handle complex drug regimens as well. In that case the
overlap is calculated from the number of nodes that are signiﬁcalty perturbed by at least two
drugs divided by the size of the affected subnetwork.
TOSðdrug1; drug2; . . .; drugMÞ ¼
 [i;j¼1...M;i6¼j neighborhooddrugi\neighborhooddrugj
[Mi¼1 neighborhooddrugi

; ð7Þ
This coefﬁcient is zero if the two neighborhoods do not overlap and 1.0 if they are identical.
The GO similarity of two drug targets—zero if no GO terms are shared, 1.0 if all terms are
shared—was calculated by the cosine coefficient as described in [46]. The GO similarity of
more drug targets or neighborhoods was in an analogous manner i.e. the GO term vectors were
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calculated from more proteins. Formally, a GO vector (gi) was built for each drug in the dataset,
where each entry of the vector represents the presence or the absence of a GO term annotated
to the drug targets. The ith entry is 1 if the ith term is annotated to the target protein, 0 other-
wise. Then the cosine similarities between drugs can be computed.
SGOðDi;DjÞ ¼ 1
gTi gj
kgikkgjk
ð8Þ
The Anatomical Therapeutic Chemical Classiﬁcation (ATC) System classiﬁes drugs into
groups at ﬁve levels in a hiearchical way. Thus the classiﬁcation system can be seen as a simple
ontology, more speciﬁcally a forest (disjoint union of trees). The roots of the individual trees
are the ﬁrst level characters/classes of the ATC system and the leaves are the full ATC codes (7
characters). There are 14 main groups at this level such as code A (Alimentary tract and metab-
olism), code B (Blood and blood forming organs), etc. One could quantify the similary beetw-
een any two ATC codes with the Resnik measure [49], which is one of the most commonly
used semantic similarity measure [31, 46]. The similarity is based on the common ancestors’s
information content (IC), that quantiﬁes the speciﬁcity and the informativity of an ATC code
level. The IC of an ATC code level (c) is the negative log likelihood of the probability of the
code (p(c)) being used. This can be estimated from the annotation frequency.
ICðcÞ ¼ log pðcÞ ð9Þ
The Resnik similarity is the most informative common ancestor (MICA) of two ATC codes:
simðATC codei;ATC codejÞ ¼ ICðMICAðATC codei;ATC codejÞÞ ð10Þ
Then one can compute the similarites between drugs by taking the maximum value of all
possible pairwise Resnik similarities between each set of ATC codes annotated to the
two drugs.
The ATC similarity is 0 if the drugs do not share any ATC codes at any level, 1.0 if they
have the exactly same ATC code annotation.
The Target Overlap Scores were then calculated for each drug pair in a database as shown in
Fig 5.
4.4. Combining drug-drug interaction measures
Pairwise and ternary combinations of the three interaction measures (TOS, GO, ATC) were
calculated by the logistic regression model [33]. Briefly, for a seriesm1,m2,. . .,mn measures to
be combined, the logical regression model will calculate a combined measureM as
Mðm1;m2; . . . ;mn Þ ¼
1
1þ eb0þ
X
bimi
ð11Þ
where the βi regression coefﬁcients are estimated by linear regression for which we used the
glmﬁt function of MATLAB (http://www.mathworks.com/help/stats/glmﬁt.html). For parame-
ter estimation, the logical regression model uses positive and negative examples. In our case,
the positive examples were the known drug combinations taken from the DCDB and the TTD
databases [29, 30]. The full evaluation pipeline is shown in Fig 5.
The data in Fig 3 were obtained using a 5 fold cross validation procedure for calculating the
combined measures using one of the four datasets indicated in the figure, combined with a 5
fold excess number of random generated drug pairs as the negative set. The cross validation
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procedure was repeated 100 times with different negative sets and the estimated distribution of
AUC values is shown in the figure.
4.5. ROC analysis
The performance of the numerical indices and index combinations was characterized by their
ability to rank positive and negative examples. We chose the method of ROC analysis as it pro-
vides a robust measure of the ranking ability of parameters [26]. In our case the choice of the
Fig 5. Flow chart of the training procedure. The input is a list of candidate combinations (i.e. combinations selected for clinical trials) and the set of known
combinations (i.e. previously approved cancer combinations). The first step is to compute the Target Overlap Score (TOS) and the drug interaction measures
(GO, ATC) for all possible drug combinations. The database consists of the random generated drugs and of the components of the candidate and the known
combinations. After the selection of the training sample (both the positive—known cancer combinations—and the negative one—random combinations) a
logistic regression was trained using the previously computed TOS and similarity values. In the next step the trained model is used for ranking a set of
candidate combinations. The output is the ranked list of the drug combinations.
doi:10.1371/journal.pone.0129267.g005
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negative sets was problematic, since the number of experimentally validated negative, unsuc-
cessful drug combinations is negligeable in the published databases and, opn the other hand,
many of the interacting drugs are apparently multitarget pharmacons while the majority of
FDA/approved drugs have one single target in the databases. We used two strategies (a and b)
to construct negative samples that circumvent these problems. a) One approach was to con-
struct binary combinations from FDA-approved drugs and leave out those combinations that
are known to have beneficial or detrimental effects. b) Random drug combinations as negative
datasets. A random drug is defined as a set of randomly selected target annotated with a ran-
domly selected ATC code. The target distribution of the drug components in the negative sam-
ple was the same as in the positive set. The targets of random drugs also have to be targeted by
at least one known, FDA approved drug. 427350 random combinations were generated in this
way. We also defined two kinds of “trivial combinations” which were separately characterized.:
i) Drug combinations having exactly the same targets in the network and ii) Combinations
consisting of structurally similar components. The structural similarity was computed with the
cdk module of Cinfony toolkit [50] and drug pairs with a Tanimoto coefficient is> 0.85 (com-
puted based on the extended fingerprints) were excluded. These two subesets were then sepa-
rately tested and the underlying combinations were excluded from the statistics of the other
positive sets.
The ranking performance was calculated by ROC analysis [26], using an 5-fold cross-valida-
tion (CV) process [51]. We repeated the the CV process 100 times using a new set of negative
samples in each round, and the average and standard deviation of (test) AUC values were re-
ported. Ass a rule, we used random drug combinations as the negative set. We also tested the
combinations of FDA approved drugs, and the tendencies of the results were found to be iden-
tical with those in Fig 2 (data not shown). Also, the differences were found significant accord-
ing to the Wilcoxon test S2 and S3 Tables, however we do not attribute special importance to
this fact. Namely, the difference between say moderate and minor interactions in the drugs.
com database seems to be qualitative, moreover there is an unexplicable number of drug com-
binations that are listed both as minor and as moderate (S4 Table).
5. Supporting Information
S1 Table. Clinical Trial Data. 1All the clinical outcome measures were recorded based on the
Response Evaluation Criteria in Solid Tumors (RECIST) [35]; 2Components in the combina-
tions: tra, lap, 5fu, cyc, epi, pac, per, doc, car, dox, gem, car, sun, ixa, oxa are trastuzumab, lapa-
tinib, fluorouracil, cyclophosphamid, epirubicin, paclitaxel, pertuzumab, docetaxel,
carboplatin, doxorubicin, gemcitabine, carboplatin, sunitinib, ixabepilone, oxaliplatin; 3 The
phase category of the given clinical study. 4Confirmed Clinical Benefit; 5Overall Response;
6Pathological Complete Response; 7Complete Response; 8Partial Response; 9Stable Disease
10Progressive Disease; 11Overall Survival Rate (in weeks); 12median Progression free survival
(in month);
(DOC)
S2 Table. Results of two-sided Wilcoxon rank sum test for all against all comparisons of
TOS scores of known drug combinations. 1All drug–drug interaction data taken from Drugs.
com (November 11, 2013) and Drug Combination Database (March 8, 2012) as described in
Methods. The TOS scores of each dataset were compared to all the other datasets and then the
p-value was reported; 2All the known detrimental and beneficial drug interactions; 3All cancer
related drug combinations; 4For detailed description of datasets see Table 1.
(DOC)
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S3 Table. Results of two-sided Wilcoxon rank sum test for TOS scores of known combina-
tions. 1For detailed description of datasets see Table 1; 2The results from two-sided Wilcoxon
rank sum tests comparing the TOS scores of known combinations to the scores of random
combinations.
(DOC)
S4 Table. Drug interactions tagged as either severe, moderate or minor. 1Name of the inter-
action partner taken from drugs; 2Drug labels taken from drugs.com
(XLS)
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